← Back to LYEL

Lyell Immunopharma, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 06/05/2026Sep 2025Filed 12/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 06/05/2026Sep 2024Filed 12/11/2025Jun 2024Filed 12/08/2025Mar 2024Filed 13/05/2025
$0$0$0$0$0$0$0$0
−$45−$24−$39−$43−$52−$45−$46−$61
−$1.92−$1.10−$2.13−$2.89−$3.54−$3.48−$3.59−$0.24
23221815254

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.